Zanubrutinib
- Generic Name
- Zanubrutinib
- Brand Names
- Brukinsa
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O3
- CAS Number
- 1691249-45-2
- Unique Ingredient Identifier
- AG9MHG098Z
- Background
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...
- Indication
Zanubrutinib is indicated for the treatment of:
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
- Associated Therapies
- -
Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 537
- Registration Number
- NCT04277637
- Locations
- 🇺🇸
UCLA Hematologyoncology, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 83
- Registration Number
- NCT04271956
- Locations
- 🇦🇹
Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria
🇩🇪Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany
🇩🇪Uniklinik Köln, Cologne, Germany
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 55
- Registration Number
- NCT04172246
- Locations
- 🇯🇵
Chiba Cancer Center, Chibashi, Chiba, Japan
🇯🇵Kanagawa Cancer Center, Yokohamashi, Kanagawa, Japan
🇯🇵Yokohama Municipal Citizens Hospital, Yokohamashi, Japan
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 500
- Registration Number
- NCT04170283
- Locations
- 🇫🇷
Chu Hopital Lyon Sud, PierreBenite, France
🇮🇹Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi, Pavia, Italy
🇯🇵Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan
Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 18
- Registration Number
- NCT04163523
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 90
- Registration Number
- NCT04116437
- Locations
- 🇺🇸
Cci Clearview Cancer Insitute, Huntsville, Alabama, United States
🇺🇸Arizona Oncology Associates, Pc Hope, Tucson, Arizona, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
- Conditions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Registration Number
- NCT04052854
- Locations
- 🇺🇸
Eisenhower Desert Cardiology Center, Rancho Mirage, California, United States
🇺🇸Sansum Clinic and Ridley Tree Cancer Center, Santa Barbara, California, United States
🇺🇸Maryland Oncology Hematology, Pa, Columbia, Maryland, United States
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 510
- Registration Number
- NCT04002297
- Locations
- 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 68
- Registration Number
- NCT03846427
- Locations
- 🇺🇸
Clinical Research Alliance, Inc, Westbury, New York, United States
🇺🇸The Charlotte Mecklenburg Hospital Authority, Charlotte, North Carolina, United States
🇦🇺The Saint George Hospital Kogarah, Kogarah, New South Wales, Australia
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- Conditions
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 230
- Registration Number
- NCT03824483
- Locations
- 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸Massachusetts General Hospital (Data Collection and Specimen Analysis), Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.